TSX: AMF
TORONTO, June 12, 2014 /CNW/ - Amorfix Life Sciences,
a product development company focused on diagnostics and
therapeutics for misfolded protein diseases, today announced that
Mr. William Wyman has been appointed
Chairman of the Board. Dr. Neil
Cashman, interim Chairman, will remain as Chief Scientific
Officer and member of the Board of Directors.
"We are extremely pleased and fortunate to have Mr. Wyman assume
the responsibility as Chairman of the Board", said Dr. Robert Gundel, Amorfix President and CEO.
"Bill brings many years of business experience leading and
developing world-class companies and his leadership will be
instrumental in bringing Amorfix to the next level. On behalf
of the entire Board of Directors, I would like to thank Dr. Cashman
for his leadership and many hours of hard work and dedication as
interim Chairman."
Mr. Wyman began his career at the management consulting firm
Booz Allen and Hamilton and
eventually became President of the Management Consulting Group, a
member of the executive committee, and a member of the Board of
Directors. Mr. Wyman co-founded the management consulting
firm, Oliver Wyman & Co. which eventually merged with the
consulting group at Marsh & McLennan under the Oliver Wyman
name. Mr. Wyman was a board member at Donaldson, Lufkin and
Jenrette and has served as a director/advisor to more than a dozen
public and private companies. He also has served as an
advisor to several private equity partnerships.
Mr. Wyman is a member of the Board of Dartmouth Hitchcock
Medical Center, and Chairman of the Norris Cotton Cancer Center
Directors Advisory Council. Mr. Wyman received his BA from
Colgate University, and his MBA from
the Harvard Business School.
About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is
an early-stage product development company developing therapeutic
antibodies and diagnostics targeting misfolded protein diseases.
Amorfix utilizes its computational discovery platform, ProMIS™, to
predict novel Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this technology, Amorfix is
developing novel antibody therapeutics and companion diagnostics
for cancer and amyotrophic lateral sclerosis (ALS). In addition,
Amorfix has developed two proprietary technologies to specifically
identify very low levels of misfolded proteins in a biological
sample: Epitope Protection™ and AMFIA™, an ultra-sensitive
dual-bead immunoassay. Use of these technologies has generated a
cerebrospinal fluid (CSF) screening test for both Alzheimer's
disease (AD) and mild cognitive impairment (MCI), and an
ultrasensitive method for detecting the hallmark of AD, aggregated
beta-Amyloid, in brain tissue, CSF and blood from animal models of
AD. For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This information
release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks
and uncertainties identified by the Company in its public
securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE Amorfix Life Sciences Ltd.